332 related articles for article (PubMed ID: 23239102)
1. Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells.
East JE; Kennedy AJ; Webb TJ
Med Res Rev; 2014 Jan; 34(1):45-76. PubMed ID: 23239102
[TBL] [Abstract][Full Text] [Related]
2. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
3. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.
Borg NA; Wun KS; Kjer-Nielsen L; Wilce MC; Pellicci DG; Koh R; Besra GS; Bharadwaj M; Godfrey DI; McCluskey J; Rossjohn J
Nature; 2007 Jul; 448(7149):44-9. PubMed ID: 17581592
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro evaluation of alpha-GalCer epimers.
Trappeniers M; Goormans S; Van Beneden K; Decruy T; Linclau B; Al-Shamkhani A; Elliott T; Ottensmeier C; Werner JM; Elewaut D; Van Calenbergh S
ChemMedChem; 2008 Jul; 3(7):1061-70. PubMed ID: 18418814
[TBL] [Abstract][Full Text] [Related]
5. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
6. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
7. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
9. Human NKT cells express granulysin and exhibit antimycobacterial activity.
Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
11. Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.
Ru W; Peijie C
Int J Biol Sci; 2009 May; 5(4):338-43. PubMed ID: 19461936
[TBL] [Abstract][Full Text] [Related]
12. A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.
Wang J; Guillaume J; Janssens J; Remesh SG; Ying G; Bitra A; Van Calenbergh S; Zajonc DM
J Biol Chem; 2019 Sep; 294(39):14345-14356. PubMed ID: 31391251
[TBL] [Abstract][Full Text] [Related]
13. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.
Wilson MT; Van Kaer L
Curr Pharm Des; 2003; 9(3):201-20. PubMed ID: 12570826
[TBL] [Abstract][Full Text] [Related]
14. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
15. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.
Hong S; Scherer DC; Singh N; Mendiratta SK; Serizawa I; Koezuka Y; Van Kaer L
Immunol Rev; 1999 Jun; 169():31-44. PubMed ID: 10450506
[TBL] [Abstract][Full Text] [Related]
16. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR.
Wun KS; Borg NA; Kjer-Nielsen L; Beddoe T; Koh R; Richardson SK; Thakur M; Howell AR; Scott-Browne JP; Gapin L; Godfrey DI; McCluskey J; Rossjohn J
J Exp Med; 2008 Apr; 205(4):939-49. PubMed ID: 18378792
[TBL] [Abstract][Full Text] [Related]
17. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
18. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
19. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
20. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
Liu Z; Guo J
Carbohydr Res; 2017 Nov; 452():78-90. PubMed ID: 29080431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
